• Advanced and Metastatic Breast Cancer 846 global 1 0.25 9 0.25 0.25 Commentary 0 1
  A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer
  Hematology-Oncology2023-03-22 20:00:00
  Aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). How do they work and when should they be added to the treatment of metastatic hormone receptor (HR)-positive breast cancer?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Adjuvant Therapy in Hormone Receptor Positive/HER2-Negative Early Breast Cancer: Case Simulations
  Hematology-Oncology2023-03-20 20:00:00
  Do you know the best approaches for identifying and managing high-risk, hormone receptor positive early breast cancer?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• 0 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Investigating Anemia and the Possibility of Pyruvate Kinase Deficiency: What Is' Your Next Step?
  Hematology-Oncology2023-03-20 20:00:00
  Did you know that pyruvate kinase deficiency (PKD) is diagnosed using a combination of PK enzyme activity and PKLR molecular profiling?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Chronic Lymphocytic Leukemia 1551 global 1 0.75 9 0.75 0.75 Commentary 0 1
  BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
  Hematology-Oncology2023-03-20 20:00:00
  Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Chronic Myelogenous Leukemia 1552 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia
  Hematology-Oncology2023-03-19 20:00:00
  How do you choose a tyrosine kinase inhibitor (TKI) for your patients with chronic myeloid leukemia (CML)? Join to hear an expert discussion on considerations and clinical data.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Colorectal Cancer 3032296 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Understanding the HER2-Positive Story and Revolutionizing the Future in Colorectal Cancer
  Hematology-Oncology2023-03-19 20:00:00
  Did you know that patients with left-sided colorectal cancer (CRC) tend to have greater overexpression of human epidermal growth factor receptor-2 (HER2) than those with right-sided disease?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Advanced and Metastatic Breast Cancer 846 global 1 0.25 9 0.25 0.25 Commentary 0 1
  A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer
  Hematology-Oncology2023-03-22 20:00:00
  Aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). How do they work and when should they be added to the treatment of metastatic hormone receptor (HR)-positive breast cancer?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Adjuvant Therapy in Hormone Receptor Positive/HER2-Negative Early Breast Cancer: Case Simulations
  Hematology-Oncology2023-03-20 20:00:00
  Do you know the best approaches for identifying and managing high-risk, hormone receptor positive early breast cancer?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• 0 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Investigating Anemia and the Possibility of Pyruvate Kinase Deficiency: What Is' Your Next Step?
  Hematology-Oncology2023-03-20 20:00:00
  Did you know that pyruvate kinase deficiency (PKD) is diagnosed using a combination of PK enzyme activity and PKLR molecular profiling?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Chronic Lymphocytic Leukemia 1551 global 1 0.75 9 0.75 0.75 Commentary 0 1
  BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
  Hematology-Oncology2023-03-20 20:00:00
  Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Chronic Myelogenous Leukemia 1552 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia
  Hematology-Oncology2023-03-19 20:00:00
  How do you choose a tyrosine kinase inhibitor (TKI) for your patients with chronic myeloid leukemia (CML)? Join to hear an expert discussion on considerations and clinical data.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Colorectal Cancer 3032296 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Understanding the HER2-Positive Story and Revolutionizing the Future in Colorectal Cancer
  Hematology-Oncology2023-03-19 20:00:00
  Did you know that patients with left-sided colorectal cancer (CRC) tend to have greater overexpression of human epidermal growth factor receptor-2 (HER2) than those with right-sided disease?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Graft Versus Host Disease and Transplant Complications 6012552 global 1 0.75 0.75 Roundtable 0 1
  Resolving Complications With Complement: Updates on the Management of HSCT-TMA
  Hematology-Oncology2023-03-19 20:00:00
  Are you up to date on emerging complement-blocking therapies for hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA)?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Multiple Myeloma 1166 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Case Challenges in Newly Diagnosed Multiple Myeloma
  Hematology-Oncology2023-03-16 20:00:00
  How do you tailor treatment to the individual patient with newly diagnosed multiple myeloma (MM)?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Multiple Myeloma 1166 global 1 1.0 9 1.0 1.0 Journal Article 0 1
  Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but Monoallelic del(1p32) Remains a Strong Prognostic Factor
  Hematology-Oncology2023-03-15 20:00:00
  In the era of risk-adapted treatment strategies, it is crucial to detect del(1p32) at multiple myeloma diagnosis, suggests a cytogenetic study.
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Chronic Kidney Disease 727 global 1 0.5 9 0.5 0.5 Clinical Review 0 1
  New Treatment Strategies for Anemia in Chronic Kidney Disease: Where Do They Fit?
  Nephrology2023-03-15 20:00:00
  What are the current treatment strategies for patients with chronic kidney disease (CKD) experiencing anemia?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Hepatocellular Carcinoma 3032322 global 1 0.75 9 0.75 0.75 Roundtable 0 1
  Peer-to-Peer Clinical Connections: Sequencing Radioligand Therapies in Metastatic Castration-Resistant Prostate Cancer
  Hematology-Oncology2023-03-13 20:00:00
  Did you know that radiopharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) care have the potential to prolong survival and optimize the quality of life?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Advanced and Metastatic Breast Cancer 846 us 1 1.0 1.0 Clinical Case 0 1
  HER2 Testing in 2023: Case Studies for Pathologists
  Pathology & Lab Medicine2023-03-13 20:00:00
  Are you up to date with the latest guidance and best practices in breast cancer human epidermal growth factor receptor 2 (HER2) testing? Learn more here!
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
  Minimizing Disparities in Breast Cancer to Enhance Equitable Cancer Care
  Hematology-Oncology2023-03-12 20:00:00
  Did you know Black women have the highest breast cancer mortality rate of any racial/ethnic group?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Bladder Cancer 821 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Medscape Onsite: Prostate and Bladder Cancer Updates From the Annual American Genitourinary Meeting
  Hematology-Oncology2023-03-09 19:00:00
  Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Head and Neck Cancer 3004984 global 1 1.0 9 1.0 2 1.0 1.0 Clinical Review 0 1
  Neuro-Oncology Updates: Insights on the Diagnosis and Management of Low-Grade Glioma, Glioblastoma, and NF1
  Hematology-Oncology2023-03-09 19:00:00
  Did you know that targeted agents and immunotherapies are improving outcomes in patients with low-grade and high-grade brain tumors?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Bowel Preparation 5000040 global 1 0.25 9 0.25 2 0.25 3 0.25 8 0.25 0.25 Clinical Brief 0 1
  How Many Patients Get a Colonoscopy After a Positive Stool Test?
  Hematology-Oncology2023-03-09 19:00:00
  A new study analyzes the rate of colonoscopies performed following a positive stool test.
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Chronic Kidney Disease 727 global 1 0.25 9 0.25 0.25 Clinical Review 0 1
  All for One in CKD Anemia Care
  Infectious Diseases2023-03-08 19:00:00
  Which specialists should be on your team in order to effectively manage anemia in patients with chronic kidney disease (CKD)?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Melanoma 65 global 1 0.25 9 0.25 0.25 Commentary 0 1
  Depicting LAG3: Exploring a New Target in Metastatic Melanoma
  Hematology-Oncology2023-03-08 19:00:00
  Do you know the role of lymphocytic activation gene 3 (LAG3) in metastatic melanoma and its potential as a treatment target?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save

Education For Your Patient

• Click here for access to online educational resources to share with your patients and their care partners

Policies and Requirements

• CME Policies
• State CME Requirements